Researchers Develop Possible 'Universal' Blood Test for Cancer
the Cancer Therapy Advisor take:
According to a study published in The Journal of the Federation of American Societies for Experimental Biology, researchers have developed a blood test that could possibly allow doctors to rule out cancer for patients with certain symptoms that are indicative of cancer. This will allow patients to avoid the expense and stress of undergoing invasive procedures, such as biopsies and colonoscopies.
The blood test would also allow doctors to diagnosis more hard-to-find cancers, which will lead to patients being put on the corresponding treatment regimen more quickly. Diana Anderson and researchers at the University of Bradford developed this blood test that identifies cancer and pre-cancerous conditions in patients with colon cancer, lung cancer, and melanoma with a high accuracy rate.
The test, called Lymphocyte Genome Sensitivity (LGS) test, focuses on white blood cell DNA. The study measured how different intensities of ultraviolet light damaged white blood cell DNA, which allowed researchers to discern between white blood cells from healthy patients and white blood cells from patients with cancer or pre-cancerous conditions. Anderson said although more research needs to be done, the results the study has yielded are remarkable.
Currently, clinical trials are being held at Bradford Royal Infirmary to assess whether patients should or should not have to undergo a colonoscopy.
A newly developed blood test could help doctors rule out cancer in patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Role of miR-125a-5p Clarified in Bladder Cancer
- Bladder Cancer Clinical Features Linked to EGFR and HER-2 Expression
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- A Vegan Diet and Cancer
- The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear